

10/20/00

PTO

Please type a plus sign (+) inside this box →

+

10-23-00

Approved for use through 09/30/2000. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. §1.53(b))

Attorney Docket No.

PC10370AADO

First Named Inventor or Application Identifier

Ghazwan Saleem Butrous,
et al

Title

TREATMENT OF PULMONARY HYPERTENSION

Express Mail Label No.

EL709318529US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☒ *Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)
2. ☒ Specification [Total Pages 20]
(preferred arrangement set forth below)
- Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference in Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. ☒ Drawing(s) (35 U.S.C. 11.3) [Total sheets 3]
4. ☒ Oath or Declaration [Total pages 3]
- a. ☒ Newly executed (original or copy/unsigned)
- b. ☐ Copy from a prior application (37 CFR §1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]
- i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§1.63(d)(2) and 1.33(b).
5. ☐ Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
- a. ☐ Computer Readable Copy
- b. ☐ Paper Copy (identical to computer copy)
- c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 C.F.R. §3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☒ Information Disclosure Statement (IDS)/PTO-1449 ☒ Copies of IDS Citations
12. ☒ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☐ *Small Entity ☐ Statement filed in prior application, Status still proper and desired
(PTO/SB/09-12)
15. ☒ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
14. ☐ Other: Priority Claim

*NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: _____

Prior application information: Examiner _____ Group/Art Unit: _____

18. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label (Insert Customer No. or Attach bar code label here) or ☒ Correspondence address below

Name Gregg C. Benson

Address Pfizer Inc.

Address Patent Department, MS 4159, Eastern Point Road

City Groton

State

CT

Zip Code

06340

Country United States Of America

Telephone

1-(860)-441-4901

Fax

1-(860)-441-5221

NAME (Print/Type) A. Dean Olson

Registration No. (Attorney/Agent)

31,185

Signature

Date

10/10/2000

FEE TRANSMITTAL

Patent fees are subject to annual revision on October 1.

These are the fees effective October 1, 2000.

Small Entity payments must be supported by a small entity statement, otherwise large entity fees must be paid. See Forms PTO/SB/09-12.

See 37 C.F.R. §§ 1.27 and 1.28

Total Amount of Payment (\$710.00)

Complete if Known

Application Number To Be Assigned
Filing Date filed herewith
First Named Inventor Ghazwan Saleem Butrous, et al
Examiner Name To Be Assigned
Group/Art Unit To Be Assigned
Attorney Docket No. PC10370AADO

10/20/00
10911 U.S. PTO
09/69287

METHOD OF PAYMENT (check one)

1. ☒ The commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number 18-1445

Deposit Account Name Pfizer Inc

☒ Charge Any Additional 37 Fee Required Under C.F.R. §§ 1.16 and 1.17. ☐ Charge the Issue Fee Set in 37 C.F.R. § 1.1.6 at the Mailing of the Notice of Allowance.

2. ☐ Payment Enclosed:

☐ Check ☐ Money Order ☐ Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
101	710	201	355	Utility filing fee	710.00
106	320	206	160	Design filing fee	
107	490	207	245	Plant filing fee	
108	710	208	355	Reissue filing fee	
114	150	214	75	Provisional filing fee	

SUBTOTAL (1) (\$) 710.00

2. EXTRA CLAIM FEES

Total Claims	Extra Claims	Fee from below	Fee Paid
10	-20**	0	-0-
Independent Claims	1	-3**	-0-
Multiple Dependent			-0-

** or number previously paid, if greater, For Reissues, see below

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description
103	18	203	9	Claims in excess of 20
102	80	202	40	Independent claims in excess of 3
104	270	204	135	Multiple dependent claim, if not paid
109	80	209	40	**Reissue independent claims over original patent
110	18	210	9	**Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$) -0-

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
105	130	205	65	Surcharge - late fee or oath	
127	50	227	25	Surcharge-late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	390	216	195	Extension for reply within second month	
117	890	217	445	Extension for reply within third month	
118	1,390	218	695	Extension for reply within fourth month	
128	1,890	228	945	Extension for reply within fifth month	
119	310	219	155	Notice of Appeal	
120	310	220	155	Filing a brief in support of an appeal	
121	270	221	135	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,240	241	620	Petition to revive - unintentional	
142	1,240	242	620	Utility issue fee (or reissue)	
143	440	243	220	Design issue fee	
144	600	244	300	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Petitions related to provisional applications	
126	240	126	240	Submission of Information Disclosure Statement	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	710	246	355	Filing a submission after final rejection (37 CFR 1.129(a))	
149	710	249	355	For each additional invention to be examined (37 CFR 1.129(b))	

Other Fee (specify)

Other Fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) -0-

SUBMITTED BY

Type or Printed Name A. Dean Olson

Signature

Date

10/11/2000

Complete (if Applicable)

Reg. Number 31,185

Deposit Account 18-1445

User ID

EXPRESS MAIL NO. EL709318529265

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: :
 GHAZWAN SALEEM BUTROUS, ET AL Examiner: **TO BE ASSIGNED**

SERIAL NO.: **TO BE ASSIGNED** :

FILED: **HEREWITH** : Art Unit: **TO BE ASSIGNED**

FOR: **TREATMENT OF PULMONARY**
 HYPERTENSION :

Hon. Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

Please amend the above-identified application as follows:

IN THE SPECIFICATION

Page 1, insert after the Title and prior to the first line the sentence --This application claims priority from U.K. application no. 0003235.9 which was filed on February 11, 2000 and U.K. application no. 9925970.7 which was filed on November 2, 1999.--

IN THE CLAIMS

Please amend claim 3 as follows:

Claim 3 (Amended) A method according to claim [1 or] 2 wherein the effective amount is less than 50 mg per day.

Please amend claim 4 as follows:

Claim 4 (Amended) A method according to claim [1 or] 2 wherein the effective amount is up to 20 mg per day.

Please amend claim 5 as follows:

Claim 5 (Amended) A method according to claim [1 or] 2 wherein the effective amount is up to 10 mg per day.

Please amend claim 6 as follows:

EXPRESS MAIL NO. EL 70931852925

Claim 6 (Amended) A method according to claim [1 or] 2 wherein the effective amount is from 1 to 10 mg per day. Please amend claim 7 as follows:

Claim 7 (Amended) A method according to [any preceding claim] claim 2 wherein the PDE5 inhibitor is administered orally.

Please amend claim 9 as follows:

Claim 9 (Amended) A method according to [any one of claims 1 to 6] claim 2 wherein the PDE5 inhibitor is inhaled.

Please Cancel claims 11-20.


REMARKS

Applicants respectfully request entry of the amendments hereinabove, and an early examination and allowance of the claims.

Please charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 16-1445. Two copies of this sheet are enclosed.

Respectfully submitted,

Date: 10/11/2000



A. Dean Olson
Reg. No. 31,185
Attorney for Applicant

Pfizer Inc.
Patent Department
Eastern Point Road
Groton, CT 06340
Tel.: (860)441-4904

Treatment of Pulmonary Hypertension

- This invention relates to the use of certain cyclic guanosine 3', 5'-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors (hereinafter PDE5 inhibitors),
5 including in particular the compound sildenafil, for the treatment of pulmonary hypertension.

- According to the specification of our International patent application WO94/28902 we have discovered that compounds which are inhibitors of the cGMP PDE5 enzyme are
10 potent and effective compounds for the treatment of male erectile dysfunction (MED, impotence) and for female sexual disorders. This discovery led to the development of the compound sildenafil (5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one) (VIAGRA™) which has proved to be outstandingly successful as the first orally effective treatment for MED.

- 15 Pulmonary hypertension is a pathological condition in which the pulmonary arterial pressure rises above normal levels and may cause sequelae of haemodynamic changes that can become life threatening. Symptoms of pulmonary hypertension include shortness of breath with minimal exertion, fatigue, dizzy spells and fainting. When pulmonary
20 hypertension occurs in the absence of a known cause, it is referred to as primary pulmonary hypertension. Primary pulmonary hypertension is rare, occurring in about two per million people worldwide.

- Secondary pulmonary hypertension is much more common occurring as a result of other
25 medical conditions, including congestive heart failure, chronic hypoxic lung disorder, including chronic obstructive pulmonary disease, inflammatory or collagen vascular diseases such as scleroderma and systemic lupus erythematosus, congenital heart diseases associated with left to right shunting and pulmonary thromboembolism.

- 30 Since pulmonary hypertension is caused typically by constriction of the pulmonary blood vessels, vascular resistance is the favoured indicator of the disease. The pulmonary vascular resistance (PVR) and systemic vascular resistance (SVR) are calculated as follows.

ADDRESS MAIL NO. EL709318529245

$$\text{PVR} = \frac{(\text{mean pulmonary artery pressure} - \text{pulmonary wedge pressure})}{\text{cardiac output}} \times 80$$


$$5 \quad \text{SVR} = \frac{(\text{mean arterial blood pressure} - \text{systemic venous pressure})}{\text{cardiac output}} \times 80$$

Agents which selectively lower PVR without significant lowering SVR remain limited.

- 10 The use of phosphodiesterase inhibitors administered endotracheally or endobronchially to treat pulmonary hypertension has been described in WO95/09636 but the compounds employed were neither particularly potent nor selective cGMP PDE inhibitors.


- According to a first aspect, the invention provides a method of treating or preventing
 15 pulmonary hypertension in a patient which comprises treating the patient with an effective amount of a PDE5 inhibitor selected from the group:

- a) sildenafil;
- b) (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;
- 20 c) 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- d)




3

e)




f)



; and

5 g)




or a pharmaceutically acceptable salt, solvate or polymorph; or a pharmaceutical composition thereof.


10 According to a second aspect, the invention provides the use of a PDE5 inhibitor selected from the group:

- a) sildenafil;
- b) (6R, 12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl) - pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;
- 15 c) 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;


d)



e)




5 f)



; and

g)



or a pharmaceutically acceptable salt, solvate or polymorph thereof; for the manufacture of a medicament for treating or preventing pulmonary hypertension.

A preferred PDE5 inhibitor is sildenafil, preferably sildenafil citrate.

For the preparation of compound a), i.e. sildenafil, (5-[2-ethoxy-5-(4-methylpiperazin-1-ylsulfonyl)phenyl]-1,6-dihydro-1-methyl-3-propylpyrazolo[4,3-d]pyrimidin-7-one) see

- 5 Example 12 of EP 0463756 (incorporated herein by reference).

For preparation of compound b), i.e. (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione (IC-351) see the compound of examples 78 and 95 of published international application WO95/19978, 10 as well as the compound of examples 1, 3, 7 and 8 (all incorporated herein by reference).

For preparation of compound c), i.e. 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (vardenafil) also known as 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-ethylpiperazine, see compound of examples 20, 19, 337 and 336 of published international application WO99/24433 (all incorporated herein by reference).

15

For preparation of compound d), see WO9605176 (incorporated herein by reference).

20

For preparation of compound e), see WO93/07124 (incorporated herein by reference).

For preparation of compounds f) and g), see Rotella D P, *J. Med. Chem.*, **2000**, 43, 1257.

25

Hereinafter, the PDE5 inhibitors defined in the first and second aspects are referred to as the compounds of the invention, and includes pharmaceutical salts, solvates or polymorphs thereof.

Advantageously, we have shown that compounds of the invention lower the PVR to a greater extent than SVR.

30

Compounds of the invention can be administered alone but, in human therapy will preferably be administered in admixture with a suitable pharmaceutical excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.

35

Compounds of the invention can be administered orally, buccally or sublingually in the form of tablets, capsules, ovules, elixirs, solutions or suspensions, which may contain flavouring or colouring agents, for immediate-, delayed-, modified-, or controlled-release applications. Tablets may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine, disintegrants such as starch (preferably corn, potato or tapioca starch), sodium starch glycolate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidone, hydroxypropylmethyl cellulose, hydroxypropylcellulose, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included. Excipients of a similar type may also be employed as fillers in gelatin capsules. Preferred excipients in this regard include lactose, starch, a cellulose, milk sugar or high molecular weight polyethylene glycols. For aqueous suspensions and/or elixirs, compounds of the invention may be combined with various sweetening or flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, ethanol, propylene glycol and glycerin, and combinations thereof.

In humans, oral administration of compounds of the invention is a preferred route. In circumstances where the recipient suffers from a swallowing disorder or from impairment of drug absorption after oral administration, the drug may be administered parenterally, sublingually or buccally.

Compounds of the invention can also be administered parenterally, for example, intracavernosally, intravenously, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally intrasternally, intracranially, intramuscularly or subcutaneously, or they may be administered by infusion techniques. For such parenteral administration they are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary. The preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art.

Compounds of the invention can also be administered intranasally or by inhalation. Inhaled formulations have advantages in delivering the active compound directly to the lung area, producing a faster effect than orally delivered formulations. For this embodiment the aerosol particle size is preferably between 0.5 micrometers and 5

- micrometers. The aerosol is conveniently generated from a pressurised container, pump, spray or nebuliser with the use of a suitable propellant, e.g dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, a hydrofluoroalkane such as 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane, carbon dioxide or other suitable gas. In the case of a pressurised aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. In a preferred embodiment, the compounds of the invention are administered by inhalation.

The term inhalation or inhaled includes endotracheal and endobronchial administration.

- Solutions of the active ingredient for use in such inhalers are prepared by conventional methods, typically by dissolving the active ingredient in water which is preferably buffered to pH 3-8, more preferably pH 4 to 7 using standard buffer systems such as citrate, lactate or phosphate buffers to control the pH. Ethanol may also be added at a concentration of up to 30% to improve aerosolisation of the formulation. Additional stabilisers may be required to improve chemical stability of the formulations; ie anti-oxidants, such as sodium metabisulphite, sodium bisulphite or tocopherol, or metal chelators such as ethylenediaminetetraacetic acid.
- Single unit-dose spray can be prepared aseptically or terminally sterilised to produce a sterile final product. Alternatively, multi-dose metered nebulisers, inhalers or atomisers can be used.
- Flavourings, perfumes and humectants may also be added to improve the patient acceptability of the formulation. Solubility enhancers e.g. caffeine can be added to improve solubility of the active drug.

- For oral and parenteral administration to human patients, the daily dosage level of the compounds of the invention will usually be less than 500 mg (in single or divided doses). Thus, for example, tablets or capsules of sildenafil may contain less than 50 mg of active compound for administration singly or two or more at a time, as appropriate. The physician in any event will determine the actual dosage which will be most suitable for any individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited and such are within the scope of this invention. The skilled person will also appreciate that, in the

treatment of certain conditions, compounds of the invention may be taken as a single dose on an "as required" basis (i.e. as needed or desired).

We have shown during studies on dog models, that pulmonary blood vessels are more sensitive to the actions of the compounds of the invention than is the *corpus cavernosum*. In the *corpus cavernosum* of the penis, a calculated intravenous dose of 12 microgrammes/kg sildenafil produced a half-maximal potentiation (ED_{50}) of nerve-induced pressure rises (see Carter A J, Ballard S A and Naylor A M, *The Journal of Urology*, (1998), volume 160, pages 242-246). In contrast a dose of only 1.5 microgrammes/kg produced a maximal response in terms of reversing hypoxic pulmonary vasoconstriction (see Biological Studies hereinafter). This is surprising in that both effects are thought to be mediated *via* the inhibition of PDE5. Accordingly a preferred dose of a compound of the invention for treating pulmonary hypertension is up to 50 mg, more preferably up to 20 mg, more preferably up to 10 mg, more preferably 1 to 10 mg. Administration of such low doses to a patient significantly reduces the risk of side effects.

A preferred PDE5 inhibitor for oral administration is sildenafil (preferably sildenafil citrate), in dosages of up to 50 mg, more preferably up to 20 mg, more preferably up to 10 mg, more preferably 1 to 10 mg.

The citrate salt of sildenafil is the preferred salt for oral administration, however other pharmaceutically acceptable salts may also be used.

Alternatively the drug may be administered as a micronised powder. The drug is micronised to give a particle size in the range 0.1 to 5 micrometres, preferably less than 1 micrometre, and then blended with a suitable lactose carrier. The powder can be placed in hard gelatin capsules for use in conjunction with a conventional dry powder inhalation device.

The inhaled formulations described above should deliver a dose of a compound of the invention of up to 50 mg, more preferably up to 20 mg, more preferably up to 10 mg, more preferably 1 to 10 mg. The exact dose administered will, however, differ depending on the subject being treated, on the severity of the condition, on the manner of administration and on the judgment of the prescribing physician. Thus, because of patient-to-patient variability, the dosages given below are a guideline only and the physician may adjust doses of the compounds to achieve the treatment that the physician considers appropriate for the patient. In considering the degree of treatment desired, the

physician must balance a variety of factors such as the age of the patient and the presence of other diseases or conditions (e.g. cardiovascular disease).

- 5 A preferred PDE5 inhibitor for inhaled administration is sildenafil, in dosages of up to 50 mg, more preferably up to 20 mg, more preferably up to 10 mg, more preferably 1 to 10 mg.

- 10 A preferred formulation for administration by inhalation comprises an aqueous formulation of sildenafil mesylate for use in an aerosol nebuliser or atomiser to provide a dose of less than 20 mg of sildenafil mesylate per dose.

- 15 The compounds of the invention can also be administered together with prostacyclins (e.g. Epoprostenol), oxygen, calcium channel blockers (e.g. Nifedipine, Diltazem, Amlodipine), endothelin antagonists (ETa), iloprost, adenosine and/or nitric oxide.

- 20 In addition to treatment of adult patients, a further application of the invention is in the treatment of very young children born with congenital heart disease. Compounds of the invention can be used to treat pulmonary hypertension in such subjects and can thus delay the immediate need for surgery until the patient is better able to withstand the trauma of surgery. Compounds of the invention can also be used to treat children who have pulmonary hypertension post operatively or due to respiratory distress syndrome or neonatal hypoxia.

- 25 Alternatively, compounds of the invention can be administered in the form of a suppository or pessary, or they may be applied topically in the form of a gel, hydrogel, lotion, solution, cream, ointment or dusting powder. Compounds of the invention may also be dermally or transdermally administered, for example, by the use of a skin patch. They may also be administered by the ocular, pulmonary or rectal routes.

- 30 Compounds of the invention may also be used in combination with a cyclodextrin. Cyclodextrins are known to form inclusion and non-inclusion complexes with drug molecules. Formation of a drug-cyclodextrin complex may modify the solubility, dissolution rate, bioavailability and/or stability property of a drug molecule. Drug-cyclodextrin complexes are generally useful for most dosage forms and administration routes. As an alternative to direct complexation with the drug the cyclodextrin may be used as an auxiliary additive, e.g. as a carrier, diluent or solubiliser. Alpha-, beta- and
- 35

gamma-cyclodextrins are most commonly used and suitable examples are described in WO-A-91/11172, WO-A-94/02518 and WO-A-98/55148.

- 5 It is to be appreciated that all references herein to treatment include curative, palliative and prophylactic treatment.

Methods of preparing such pharmaceutical compositions with a certain amount of active ingredient are well known to those skilled in this art, or may be determined by reference to literature precedents.

10

Examples of particular formulations are included hereinafter to further illustrate the invention. The examples are illustrative only and are not intended to limit the scope of the invention.

15 Example 1

A Tablet Formulation for Oral Use

Sildenafil citrate (20 mg) is blended with cellulose (microcrystalline), silicon dioxide, stearic acid (fumed) and the mixture is compressed to form tablets.

20 Example 2

An Intravenous Formulation

Sildenafil citrate	100mg
isotonic saline	1,000ml

Example 3Dry Powder Formulation for Inhalation

A dry powder formulation of sildenafil citrate was prepared by blending micronised drug (1 g) with lactose suitable for inhalation use, e.g. Pharmatose (trade mark), 325 mesh, (10 g) to provide a homogeneous blend. The product was filled into hard gelatin capsules (150 mg) for use with a commercial dry powder inhalation device.

Similar formulations may be prepared of sildenafil mesylate and sildenafil free base.

10 Example 4Solution Formulation for Inhalation

A solution was prepared of sildenafil mesylate having the following composition:

Sildenafil mesylate	10g
Sodium dihydrogen phosphate	0.69g
Distilled water	90ml
Ethanol	10ml

- 15 The solution was stirred to dissolve the ingredients and the pH adjusted to 4.2 by the addition of 1M sodium hydroxide solution. The solution was filter sterilised and aseptically filled into amber nebuliser bottles. This solution may then be used with commercial nebulisers or atomisers to dose 10 mg of active drug.
- 20 Preparation of 5-[2-ethoxy-5-(4-methylpiperazin-1-ylsulphonyl)phenyl]-1, 6-dihydro-1-methyl-3-propylpyrazolo [4,3-d]pyrimidin-7-one) methanesulphonate salt (sildenafil mesylate)
- 5-[2-Ethoxy-5-(4-methylpiperazin-1-ylsulphonyl)phenyl]-1, 6-dihydro-1-methyl-3-propylpyrazolo[4,3-d]pyrimidin-7-one (sildenafil, see EP 0463756 Example 12 for preparation) (100g, 0.21 mol) was dissolved in boiling acetone (3000 ml).
- 25 Methanesulphonic acid (14.9 ml, 0.23 mol) was added to the hot acetone solution. Within 10 seconds a precipitate formed. The mixture was allowed to cool and granulate for 48 hours. The title product was collected by filtration and dried in vacuum to give a white crystalline solid (116.0 g, 96.8%), m.p. 272-274°C; Found: C, 48.33; H, 5.99; N, 14.68.
- 30 $C_{23}H_{34}N_6O_7S_2$ requires C, 48.41; H, 6.00; N, 14.73%; $\delta(CD_3SOCD_3)$ 0.92 (3H, t), 1.33 (3H, t), 1.73 (2H, heptet), 2.29 (3H, s), 2.77 (2H, t), 2.79 (3H, s), 3.16 (2H, br), 3.3-3.57 (4H,

br), 3.8 (2H, br), 4.16 (3H, s), 4.20(2H, q), 7.4 (1H, d), 7.88 (1H, dd), 7.90 (1H, s) and 9.44 (1H, br).

Clinical Study

- 5 The efficacy of sildenafil in pulmonary hypertension in human patients was demonstrated by the following study.

A number of patients having various causes of pulmonary hypertension were selected.

The patients were then assessed in order to establish baseline data, including

- 10 haemodynamic parameters (by right heart catheterisation), blood gas profile (via an arterial line and pulse oximetry). The patients were then tested with 40 ppm of nitric oxide (NO) by inhalation for 5 minutes to assess the reversibility of pulmonary hypertension. Haemodynamic parameters were reassessed within 5 minutes of NO and then further assessed 5 -20 minutes later. When the pulmonary arterial pressure levels had returned
- 15 to baseline (+5%) inhalation haemodynamic parameters were assessed again and patients were continuously infused with sildenafil at rates to control the plasma level at 100, 300 and 500 nanogrammes per millilitre. A few patients received placebo instead of sildenafil in double-blind fashion. Haemodynamic parameters were recorded throughout infusion.

20

From the data collected during the trial, the PVR and SVR were determined. The results are shown in Figure 1 and demonstrate a significant reduction in PVR experienced in a number of patients, confirming the utility of sildenafil for this indication. Furthermore, the results demonstrate that the effect of sildenafil on the SVR was substantially lower than

25 the effect on PVR.

Biological Studies

The efficacy of sildenafil for treating pulmonary hypertension in dogs was demonstrated by the following studies. The first study examined efficacy via intravenous administration.

- 30 The second study examined efficacy via inhaled administration.

Intravenous Administration

The anaesthetised dog is the model of choice in which to study the effects of drugs, owing to the similarity between canine and human haemodynamics, and additionally, to

35 ensure consistency between pharmacological and toxicological species.

Beagle dogs of either sex were anaesthetised with intravenous sodium pentobarbitone (Sagatal [trademark], 30 to 45 mg/kg) and anaesthesia maintained with an infusion of Sagatal (6 mg/kg/h) into the right femoral vein. The dogs were initially intubated via the mouth, and then via a tracheotomy, and artificially respired using an Ugo Basille dog
5 respirator. If necessary respiratory reflexes were abolished by the administration of pancuronium (0.2 mg/kg, at 60 to 90 minute intervals). Respiratory gases (inspired O₂ and end tidal CO₂) were monitored by a Normocap 200 (trademark) respiratory gas monitor (Datex Instrumentarium Corp.). The depth of anaesthesia was assessed by carefully monitoring arterial blood pressure and heart rate. The left femoral vein and
10 artery were cannulated for dose administration and recording arterial blood pressure, respectively. The right jugular vein was cannulated with a Swan Ganz catheter, the tip of which was positioned by means of pressure monitoring in a branch of the pulmonary artery. Pulmonary artery pressure (PAP) and pulmonary artery wedge pressure were recorded from this catheter. This catheter was also connected to a cardiac index
15 computer (Gould Instruments) and cardiac output determined by thermodilution following rapid injection of 5 ml saline at room temperature. All catheters were filled with heparinised saline. Lead II ECG was recorded from 2 stainless steel needles inserted subcutaneously in the right arm and left leg. All transducers and recording electrodes were connected to HSE preamplifiers. All data from the primary signals (PAP, Arterial
20 blood pressure (ABP) and ECG) was recorded on a Po-ne-mah (trademark) data acquisition system. From these signals the following parameters were derived; systolic, diastolic and mean blood pressure, systolic, diastolic and mean pulmonary artery pressure, pulmonary capillary wedge pressure. Heart rate was recorded from both the blood pressure and ECG signals, for verification checks of the analysis algorithms.
25

Arterial blood samples were taken at intervals to monitor blood gases using an ABL505 blood gas analyser (Radiometer Ltd.). Throughout the experiment Hartmans solution was infused at a rate appropriate to maintain blood acid/base balance and volume. Core temperature was maintained at approximately 38°C by means of a Harvard
30 Homeothermic blanket. Following preparatory surgery, the animals were allowed to stabilise for approximately 30 minutes.

The haemodynamic parameters were logged by the data acquisition system as the mean values from complete cardiac cycles every 10 seconds. The computer file containing
35 these values constitutes the raw data for the study. During the control periods inspired oxygen was at a concentration of 40%. Hypoxia was produced by adding nitrogen to the inspiratory gas mixture at a rate sufficient to reduce inspired oxygen to 10%. Hypoxic

conditions were maintained for 15 minutes during which time cardiac output estimations were taken at 5 minute intervals. Following this hypoxic challenge the dog was returned to control conditions for 30 minutes before the next challenge. Three baseline measurements of all parameters were taken at 5 minute intervals prior to the animals receiving an hypoxic challenge. These baseline readings check the stability of the preparation. Two hypoxic challenges were conducted before the addition of any compound or vehicle.

Each intravenous dose of sildenafil consisted of a 2 minute loading infusion starting 15 minutes before an hypoxic challenge, followed by a maintenance infusion which continued throughout the hypoxic challenge and subsequent normoxia until the next dose is given. Vehicle was given at the same infusion rates as those used for sildenafil and the rate of the infusions did not exceed 2 ml/minute. A 2 ml sample of arterial blood was taken at pre dose and just prior to the end of each infusion, the plasma frozen and the drug content was analysed.

Doses were made up by dissolving sildenafil in vehicle [sodium acetate buffer (0.038 M)] to the required concentration. Four doses of 1.5, 4.5, 15 and 45 microgrammes/weight of dog in kilogrammes were administered.

The results are shown in Figure 2, which shows the effect on PVR and SVR against dose. The results show a maximal effect on the PVR at the lowest dose of 1.5 microgrammes/kg. The effect on SVP is significantly lower than on PVP.

25 Inhaled Administration


This separate study was performed in analogous fashion to intravenous administration, except that doses were administered into the inspiratory limb of the respiratory circuit using a Penta-sonic Nebuliser (deVilbiss). Each inhaled dose consisted of a timed nebulisation of the solution at a respiration rate of 15 breaths/min finishing 5 min before an hypoxic challenge. Sildenafil and vehicle were administered to a maximum of four dogs per group (i.e. total of eight dogs). At the end of the first vehicle experiment an additional hypoxic challenge was done following administration of an inhaled dose of sildenafil.

35 Doses were made up by dissolving sildenafil in vehicle [sodium acetate buffer (0.038 M)] to the required concentration. Four doses of 30, 80, 230 and 770 microgrammes/weight of dog in kilogrammes were administered.


The results are shown in Figure 3, which shows the effect of dose against PVR and SVR. The results show a maximal effect on the PVP at the lowest dose of 30 microgrammes/kg.

Claims


- 1 A method of treating or preventing pulmonary hypertension in a patient which
 5 comprises treating the patient with an effective amount of a PDE5 inhibitor
 selected from the group:
- a) sildenafil;
- b) (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;
- c) 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
- 10 d)



e)




f)



; and

g)



or a pharmaceutically acceptable salt, solvate or polymorph; or a pharmaceutical composition thereof.

5

2 A method according to claim 1 wherein the PDE5 inhibitor is sildenafil.

3 A method according to claim 1 or 2 wherein the effective amount is less than 50
mg per day.

10

4 A method according to claim 1 or 2 wherein the effective amount is up to 20 mg
per day.

5 A method according to claim 1 or 2 wherein the effective amount is up to 10 mg
per day.

15

6 A method according to claim 1 or 2 wherein the effective amount is from 1 to 10
mg per day.

20 7 A method according to any preceding claim wherein the PDE5 inhibitor is
administered orally.


8 A method according to claim 7 wherein the PDE5 inhibitor is sildenafil citrate.

25 9 A method according to any one of claims 1 to 6 wherein the PDE5 inhibitor is
inhaled.


10 A method according to claim 9 wherein the PDE5 inhibitor is sildenafil mesylate.

11 The use of a PDE5 inhibitor selected from the group:


- a) sildenafil;
 b) (6R, 12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione;
 5 c) 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;
 d)



e)




f)



g)

19



or a pharmaceutically acceptable salt, solvate or polymorph thereof; for the manufacture of a medicament for treating or preventing pulmonary hypertension.

- 5 12 The use according to claim 11 wherein the PDE5 inhibitor is sildenafil.
- 13 The use according to claim 11 or 12 wherein the effective amount is less than 50 mg per day.
- 10 14 The use according to claim 11 or 12 wherein the effective amount is up to 20 mg per day.
- 15 The use according to claim 11 or 12 wherein the effective amount is up to 10 mg per day.
- 15 16 The use according to claim 11 or 12 wherein the effective amount is from 1 to 10 mg per day.
- 17 The use according to any one of claims 11 to 16 wherein the PDE5 inhibitor is administered orally.
- 20 18 The use according to claim 17 wherein the PDE5 inhibitor is sildenafil citrate.
- 19 The use according to any one of claims 11 to 16 wherein the PDE5 inhibitor is inhaled.
- 25 20 The use according to claim 19 wherein the PDE5 inhibitor is sildenafil mesylate.

Abstract

This invention relates to the use of certain cyclic guanosine 3', 5'-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of pulmonary hypertension.

Figure 1




Figure 2





Figure 3



Please type a plus sign (+) inside this box →

+

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63) <input type="checkbox"/> Declaration submitted with Initial Filing		Attorney Docket Number	PC10370AADO
		First Named Inventor	Ghazwan Saleem Butrous, et al
		COMPLETE IF KNOWN	
		Application Number	To Be Assigned
		Filing Date	filed herewith
<input type="checkbox"/> Declaration Submitted after Initial Filing (surcharge 37 CFR 1.16 (e)) required)		Group Art Unit	To Be Assigned
		Examiner Name	To Be Assigned

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

TREATMENT OF PULMONARY HYPERTENSION

(Title of the Invention)

☒ the specification of which is attached hereto

OR

☐ was filed on (MM/DD/YYYY) _____ as United States Application Number or PCT International

Application Number _____ and was amended on (MM/DD/YYYY) _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
0003235.9	UK	February 11, 2000 02/11/2000	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
9925970.7	UK	November 2, 1999 11/02/1999	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below:

Application Number(s)	Filing Date (MM/DD/YYYY)	
		<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B sheet attached hereto.

EXPRESS MAIL NO. EL709318529245

Please type a plus sign (+) inside this box →

+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

DECLARATION ---- Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 U.S.C. 1.56, which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)

☐ Additional U.S. or PCT International application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

☐ Customer Number

or

☒ Registered practitioner(s) name/registration number listed below

Place Customer
Number Bar Code
Label here

Name	Registration Number	Name	Registration Number
Peter C. Richardson	27,526	Lawrence C. Akers	28,587
Allen J. Spiegel	25,749	A. Dean Olson	31,185
Paul H. Ginsburg	28,718	Mervin E. Brokke	32,723
J. Trevor Lumb	28,567	Valerie M. Fedowich	33,688
James T. Jones	30,561	Bryan C. Zielsinski	34,462
Gregg C. Benson	30,997	Robert T. Ronau	36,257
Robert F. Sheyka	31,304	B. Timothy Creagan	39,156
Grover F. Fuller Jr.	31,760	Alan L. Koller	37,371
Karen DeBenedictis	32,977	Jolene W. Appleman	35,428
Lorraine B. Ling	35,251	Kristina L. Konstas	37,864
Garth Butterfield	36,997	Seth H. Jacobs	32,140
Carl J. Goddard	39,203	Martha A. Gammill	31,820
Raymond M. Speer	26,810	Gregory P. Raymer	36,647
Jennifer A. Kispert	40,049	E. Victor Donahue	35,492
Israel Nissenbaum	27,582	Todd M. Crissey	37,807
Deborah A. Martin	44,222	Roy F. Waldron	42,208
A. David Joran	37,858	Adrian G. Looney	41,406
Elsa Djuardi	45,963	Jeffrey N. Myers	41,213
Gabriel L. Kleiman	40,681	Michelle A. Sherwood	36,271

☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to: ☐ Customer Number or Bar Code Label OR ☒ Correspondence address below

Name	Gregg C. Benson				
Address	Pfizer Inc.				
Address	Patent Department, MS 4159, Eastern Point Road				
City	Groton	State	CT	Zip Code	06340
Country	United States Of America	Telephone	1-(860)-441-4901	Fax	1-(860)-441-5221

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor: ☐ A petition has been filed for this unsigned inventor

Given Name (first and middle (if any))		Family Name or Surname	
Ghazwan Saleem		BUTROUS	
Inventor's Signature	Date		
Residence: City	State	Country	Citizenship
Post Office Address	UK	UK	UK
Post Office Address c/o Pfizer Inc. 235 East 42nd Street			
City	New York	State	NY
Zip	10017	Country	USA

☒ Additional inventors are being named on the supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto.

Please type a plus sign (+) inside this box

+

DECLARATION

ADDITIONAL INVENTOR(S)
Supplemental Sheet

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor					
Given Name (first and middle (if any))				Family Name or Surname			
Timothy Michael				LUKAS			
Inventor's Signature						Date	
Residence: City		State		Country		UK	
Post Office Address							
Post Office Address		Pfizer, Inc. 235 East 42nd Street					
City		New York		State		NY	
		Zip		10017		Country	
						USA	
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor					
Given Name (first and middle (if any))				Family Name or Surname			
Ian				MACHIN			
Inventor's Signature						Date	
Residence: City		State		Country		UK	
Post Office Address							
Post Office Address		c/o Pfizer Inc 235 East 42nd Street					
City		New York		State		NY	
		Zip		10017		Country	
						USA	
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor					
Given Name (first and middle (if any))				Family Name or Surname			
Inventor's Signature						Date	
Residence: City		State		Country		Citizenship	
Post Office Address							
Post Office Address							
City		State		Zip		Country	
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor					
Given Name (first and middle (if any))				Family Name or Surname			
Inventor's Signature						Date	
Residence: City		State		Country		Citizenship	
Post Office Address							
Post Office Address							
City		State		Zip		Country	